NCT07891572Enrolling by invitation
Oxaliplatin-Based Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma**
Efficacy and Safety of Oxaliplatin-Based Doublet Regimens as Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma
Source: ClinicalTrials.gov · Last updated 23 Oct 2026
Brief summary (registry, in English)
Patients with pathologically-confirmed gastrointestinal neuroendocrine carcinoma will be enrolled, to explore the efficacy and safety of oxaliplatin-based doublet chemotherapy in the adjuvant treatment of gastrointestinal neuroendocrine carcinoma. For patients after radical resection, adjuvant chemotherapy is recommended. XELOX, SOX or FOLFOX regimens can be selected based on the patient's physical status. Single-agent chemotherapy alone is not recommended.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 42 (estimated)
- First submitted
- 15 Sept 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2031
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT07891572
What you commit to
- Study type: Observational
- Planned participants: 42
- From Sept 2026 to the primary completion date, Sept 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of another concurrent malignant tumour within 5 years prior to enrolment;
- Received any anti-tumour therapy within six months before enrolment;
- In the investigator's judgment, the patient has concomitant diseases (such as uncontrolled hypertension, severe diabetes, thyroid disorders, psychiatric diseases, etc.) or any other conditions that would seriously endanger patient safety or prevent completion of this study.
Who the study is looking for
- Histopathologically-confirmed diagnosis of gastrointestinal neuroendocrine carcinoma
- Patients with radical resection of tumour, unresectable locally-advanced disease or metastatic disease, regardless of tumour stage;
- No restriction on gender, aged between 18 and 75 years old;
- Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1. Hematological, hepatic and renal function parameters meet the criteria for chemotherapy administration;
- Expected survival time ≥ 3 months;
- Agree to undergo examinations, treatment and follow-up in accordance with this study protocol; agree to provide clinicopathological and follow-up data required for the study; and consent to the use of study-related data for subsequent research;
- Voluntarily participate in this clinical trial, understand the study procedures and be capable of signing the informed consent form.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.